vs

Side-by-side financial comparison of IM Cannabis Corp. (IMCC) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.

IM Cannabis Corp. is the larger business by last-quarter revenue ($9.3M vs $5.0M, roughly 1.8× cbdMD, Inc.). IM Cannabis Corp. runs the higher net margin — -1.5% vs -5.6%, a 4.1% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -13.9%).

IM Cannabis Corp is a global cannabis enterprise focused on the cultivation, production, distribution and retail of medical and adult-use cannabis products. It runs business across core markets including North America, the European Union and Israel, offering branded cannabis goods, wellness derivatives and related consumer products to medical patients and recreational users.

cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.

IMCC vs YCBD — Head-to-Head

Bigger by revenue
IMCC
IMCC
1.8× larger
IMCC
$9.3M
$5.0M
YCBD
Growing faster (revenue YoY)
YCBD
YCBD
+12.0% gap
YCBD
-1.9%
-13.9%
IMCC
Higher net margin
IMCC
IMCC
4.1% more per $
IMCC
-1.5%
-5.6%
YCBD

Income Statement — Q2 FY2025 vs Q1 FY2026

Metric
IMCC
IMCC
YCBD
YCBD
Revenue
$9.3M
$5.0M
Net Profit
$-141.6K
$-283.1K
Gross Margin
27.0%
59.8%
Operating Margin
-2.8%
-5.7%
Net Margin
-1.5%
-5.6%
Revenue YoY
-13.9%
-1.9%
Net Profit YoY
94.4%
-1975.7%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMCC
IMCC
YCBD
YCBD
Q4 25
$5.0M
Q3 25
$4.7M
Q2 25
$9.3M
$4.6M
Q1 25
$4.7M
Q4 24
$5.1M
Q3 24
$4.6M
Q2 24
$10.8M
$5.2M
Q1 24
$4.4M
Net Profit
IMCC
IMCC
YCBD
YCBD
Q4 25
$-283.1K
Q3 25
$-680.0K
Q2 25
$-141.6K
$-895.3K
Q1 25
$-480.8K
Q4 24
$15.1K
Q3 24
$-152.8K
Q2 24
$-2.5M
$459.7K
Q1 24
$-3.0M
Gross Margin
IMCC
IMCC
YCBD
YCBD
Q4 25
59.8%
Q3 25
58.8%
Q2 25
27.0%
61.5%
Q1 25
62.3%
Q4 24
66.5%
Q3 24
53.9%
Q2 24
5.7%
65.8%
Q1 24
59.0%
Operating Margin
IMCC
IMCC
YCBD
YCBD
Q4 25
-5.7%
Q3 25
-14.5%
Q2 25
-2.8%
-19.6%
Q1 25
-10.2%
Q4 24
-1.7%
Q3 24
-6.9%
Q2 24
-19.5%
-7.4%
Q1 24
-35.4%
Net Margin
IMCC
IMCC
YCBD
YCBD
Q4 25
-5.6%
Q3 25
-14.4%
Q2 25
-1.5%
-19.4%
Q1 25
-10.1%
Q4 24
0.3%
Q3 24
-3.4%
Q2 24
-23.4%
8.9%
Q1 24
-68.8%
EPS (diluted)
IMCC
IMCC
YCBD
YCBD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$-0.15
Q1 24
$-1.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMCC
IMCC
YCBD
YCBD
Cash + ST InvestmentsLiquidity on hand
$579.6K
$3.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.0M
$9.0M
Total Assets
$30.0M
$11.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMCC
IMCC
YCBD
YCBD
Q4 25
$3.4M
Q3 25
$2.3M
Q2 25
$579.6K
$1.1M
Q1 25
$1.8M
Q4 24
$2.0M
Q3 24
$2.5M
Q2 24
$511.0K
$2.4M
Q1 24
$2.1M
Stockholders' Equity
IMCC
IMCC
YCBD
YCBD
Q4 25
$9.0M
Q3 25
$7.2M
Q2 25
$3.0M
$6.1M
Q1 25
$665.8K
Q4 24
$1.8M
Q3 24
$2.0M
Q2 24
$4.0M
$3.0M
Q1 24
$3.1M
Total Assets
IMCC
IMCC
YCBD
YCBD
Q4 25
$11.8M
Q3 25
$10.4M
Q2 25
$30.0M
$9.9M
Q1 25
$10.9M
Q4 24
$11.5M
Q3 24
$10.6M
Q2 24
$29.4M
$13.8M
Q1 24
$14.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMCC
IMCC
YCBD
YCBD
Operating Cash FlowLast quarter
$-812.5K
Free Cash FlowOCF − Capex
$-977.3K
FCF MarginFCF / Revenue
-19.5%
Capex IntensityCapex / Revenue
3.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMCC
IMCC
YCBD
YCBD
Q4 25
$-812.5K
Q3 25
$-240.7K
Q2 25
$-704.2K
Q1 25
$-189.5K
Q4 24
$-317.9K
Q3 24
$167.4K
Q2 24
$289.8K
Q1 24
$-704.1K
Free Cash Flow
IMCC
IMCC
YCBD
YCBD
Q4 25
$-977.3K
Q3 25
$-243.6K
Q2 25
$-705.7K
Q1 25
$-205.0K
Q4 24
$-482.3K
Q3 24
$157.4K
Q2 24
Q1 24
$-708.7K
FCF Margin
IMCC
IMCC
YCBD
YCBD
Q4 25
-19.5%
Q3 25
-5.2%
Q2 25
-15.3%
Q1 25
-4.3%
Q4 24
-9.4%
Q3 24
3.5%
Q2 24
Q1 24
-16.2%
Capex Intensity
IMCC
IMCC
YCBD
YCBD
Q4 25
3.3%
Q3 25
0.1%
Q2 25
0.0%
Q1 25
0.3%
Q4 24
3.2%
Q3 24
0.2%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
IMCC
IMCC
YCBD
YCBD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-21.06×
Q3 24
Q2 24
0.63×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMCC
IMCC

Segment breakdown not available.

YCBD
YCBD

Sales Channel Directly To Consumer$3.6M72%
Sales Channel Through Intermediary$1.4M28%

Related Comparisons